# Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

> **NCT05595889** · PHASE2 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Small Cell Lung Cancer
- Angiogenesis
- Chemotherapy Effect

## Interventions

- **DRUG:** Surufatinib
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT05595889
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05595889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05595889, "Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05595889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*